로그인시 본인확인과정이 필요할 수 있습니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기
| 국가/구분 | United States(US) Patent 등록 |
|---|---|
| 국제특허분류(IPC7판) |
|
| 출원번호 | US-0005568 (2011-01-13) |
| 등록번호 | US-8318692 (2012-11-27) |
| 발명자 / 주소 |
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
|
| 인용정보 | 피인용 횟수 : 0 인용 특허 : 326 |
Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding a
Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
1. A method for treating cancer in a subject, comprising: administering to said subject an effective amount of an anti-PAX2 agent, wherein said anti-PAX2 agent comprises an oligonucleotide containing a PAX2 binding site of DEFB1 promoter, wherein said PAX2 binding site of DEFB1 promoter comprises th
1. A method for treating cancer in a subject, comprising: administering to said subject an effective amount of an anti-PAX2 agent, wherein said anti-PAX2 agent comprises an oligonucleotide containing a PAX2 binding site of DEFB1 promoter, wherein said PAX2 binding site of DEFB1 promoter comprises the nucleotide sequence of SEQ ID NO:1 or the nucleotide sequence complementary to SEQ ID NO:1. 2. The method of claim 1, wherein said PAX2 binding site of DEFB1 promoter comprises the nucleotide sequence of SEQ ID NO:17 or the nucleotide sequence complementary to SEQ ID NO:17. 3. The method of claim 2, wherein said PAX2 binding site of DEFB1 promoter comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:18-21, 25, 26, 28 and 29 and nucleotide sequences complementary to SEQ ID NOS:18-21, 25, 26, 28 and 29. 4. The method of claim 3, wherein said PAX2 binding site of DEFB1 promoter comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:18-21 and nucleotide sequences complementary to SEQ ID NOS:18-21. 5. The method of claim 1, wherein said oligonucleotide is conjugated to an antibody, a receptor or a receptor ligand to target a tumor tissue in said subject. 6. A method for treating cancer in a subject, comprising: administering to said subject an effective amount of an anti-PAX2 agent,wherein said anti-PAX2 agent expresses an oligonucleotide that inhibits PAX2 binding to the DEFB1 promoter in a cancer cell. 7. The method of claim 6, wherein said oligonucleotide comprises a PAX2 binding site of DEFB1 promoter, and wherein said PAX2 binding site of DEFB1 promoter comprises the nucleotide sequence of SEQ ID NO:1 or the nucleotide sequence complementary to SEQ ID NO:1. 8. The method of claim 6, wherein said PAX2 binding site of DEFB1 promoter comprises the nucleotide sequence of SEQ ID NO:17 or the nucleotide sequence complementary to SEQ ID NO:17. 9. The method of claim 6, wherein said PAX2 binding site of DEFB1 promoter comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:18-21, 25, 26, 28 and 29 and nucleotide sequences complementary to SEQ ID NOS:18-21, 25, 26, 28 and 29. 10. The method of claim 6, wherein said anti-PAX2 agent comprises a viral vector capable of expressing an oligonucleotide containing a PAX2 binding site of DEFB1 promoter, wherein said PAX2 binding site of DEFB1 promoter comprises the nucleotide sequence of SEQ ID NO:1 or the nucleotide sequence complementary to SEQ ID NO:1. 11. The method of claim 10, wherein said viral vector comprises a regulatory element that controls expression of said oligonucleotide in said cancel cell. 12. The method of claim 6, wherein said anti-PAX2 agent comprises a plasmid vector capable of expressing an oligonucleotide containing a PAX2 binding site of DEFB1 promoter, wherein said PAX2 binding site of DEFB1 promoter comprises the nucleotide sequence of SEQ ID NO:1 or the nucleotide sequence complementary to SEQ ID NO:1. 13. The method of claim 12, wherein said plasmid vector comprises a regulatory element that controls expression of said oligonucleotide in said cancel cell. 14. The method of claim 12, wherein said plasmid is conjugated to an antibody, a receptor or a receptor ligand to target a tumor tissue in said subject. 15. A composition for treating cancer in a subject, comprising: (1) a pharmaceutically acceptable carrier; and(2) an effective amount of an oligonucleotide that inhibits the binding of PAX2 to DEFB1 promoter, or an expression vector that is capable of expressing said oligonucleotide in a cancer cell,wherein said oligonucleotide comprises a PAX2 binding site of DEFB1 promoter and said PAX2 binding site of DEFB1 promoter comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:18-21, 25, 26, 28 and 29 and nucleotide sequences complementary to SEQ ID NOS:18-21, 25, 26, 28 and 29. 16. The composition of claim 15, wherein said expression vector is a viral vector. 17. The composition of claim 15, wherein said expression vector is a plasmid vector.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.